GABA-B

The GABA-B receptor is one of two main receptor families that respond to GABA (GABA), the brain's primary inhibitory neurotransmitter. Unlike its sibling, the GABA-A, GABA-B is a metabotropic receptor — meaning it does not open an ion channel directly, but instead works through a slower chain of intracellular signals.

GABA-B receptors are found throughout the central and peripheral nervous system, sitting on both the sending and receiving sides of synapses. Their defining feature is the quality of inhibition they produce: slower to start, longer-lasting, and more modulatory than the rapid inhibition that GABA-A handles.

How it works · its role

GABA-B receptors are coupled to G-proteins (specifically Gi/Go). When GABA or another agonist binds, the receptor triggers a cascade that reduces the activity of adenylyl cyclase, opens inwardly rectifying potassium channels, and inhibits voltage-gated calcium channels.

The potassium channel effect hyperpolarises the neuron — making it harder to fire. The calcium channel effect is especially important at presynaptic terminals, where it reduces the release of other neurotransmitters, including dopamine, glutamate, and noradrenaline.

This dual action — quieting the receiving cell and dampening transmission from the sending cell — gives GABA-B a broad modulatory role. It acts as a kind of volume control, smoothing out excitatory activity across multiple systems rather than simply switching a single channel on or off.

Relevance to substances & effects

The most pharmacologically significant substances acting at GABA-B are baclofen and GHB (gamma-hydroxybutyrate). Baclofen is a selective GABA-B agonist used clinically for muscle spasticity and, in some settings, alcohol use disorder. GHB, which occurs naturally in the brain at very low levels, is both a GABA-B agonist and the target of its own distinct receptor, and is used recreationally and medically (as sodium oxybate for narcolepsy).

Alcohol activates GABA-B receptors as part of its broader depressant profile, contributing to muscle relaxation and sedation. The GABA-B system is also implicated in the effects of gabapentinoids — gabapentin and pregabalin — though their primary mechanism is through calcium channel subunits rather than direct GABA-B agonism.

Subjective effects associated with GABA-B activation include muscle relaxation, sedation, euphoria, and at higher doses, dissociative or anaesthetic-like states. Because GABA-B modulates dopamine release in reward circuits, it is also relevant to understanding how several depressant substances produce their reinforcing effects.

Tolerance & dependence

Regular use of GABA-B agonists produces tolerance and physical dependence. Baclofen and GHB are both associated with dependence syndromes; abrupt withdrawal from either can include anxiety, insomnia, tremor, and in severe cases seizures or psychosis.

Withdrawal from high-dose baclofen is considered medically serious and typically requires a slow, supervised taper. GHB dependence is particularly difficult to manage because of its short half-life, which produces rapid-cycling withdrawal symptoms.

Cross-tolerance between GABA-B-active substances and other CNS depressants — including alcohol and benzodiazepines — is partial and clinically relevant in detoxification settings.